NCBS Home page
Accession List
Pathway List
Search
Authorized Users
Help
News archives

Accession Type:
Pathway
NMArginine
NMArginine

Enter a Search String

Special character and space not allowed in the query term. Search string should be at least 2 characters long.
Search in: Search for Match By

Accession information for NMArginine (Accession Number 74)

Reaction Scheme

Accession Basic Parameters

Name NMArginine
Accession Type Pathway
Transcriber Sharat J. Vattyaden and Prasoon Agarwal, NCBS
Developer Abu-Soud HM, Wang J, Rousseau DL, and Stuehr DJ
Entry Date (YYYY-MM-DD) 2006-08-07
Species human
Tissue Kidney cell expressing the rat brain nNOS
Cell Compartment Cytosol
Source Abu-Soud HM et al. Biochemistry. 1999 Sep 21;38(38):12446-51. ( Peer-reviewed publication )
Methodology Quantitative match to experiments
Model Implementation Exact GENESIS implementation
Model Validation Approximates original data
Notes This model is taken from the Abu-Soud HM et al. Biochemistry. 1999 Sep 21;38(38):12446-51. This model shows kinetic binding of NMArginine to neuronal nitric oxide synthase.
Model shows the substrate (NM-Arginine) binding to nNOS in a two-step reversible fashion. First there is rapid binding equilibrium between Im-nNOS and NM-Arginine to form an intermediate that contains bound imidazole and NM-arginine. This is followed by a slower conformational change in the Im-enzyme-substrate complex that is associated with release of bound imidazole and generation of a modified enzyme-substrate complex which is detected due to spectral change. Rates approximated based on data in Table 2. The rates for first reaction are not exact since only Kd known and appropriate graphs do not exist for matching the kinetic profile.

Conversion formats

FormatFile
Native Format (GENESIS format)    acc74.g   
MATLAB format    acc74.m   
SBML format    acc74.xml   



Database compilation and code copyright (C) 2005, Upinder S. Bhalla and NCBS/TIFR
This Copyright is applied to ensure that the contents of this database remain freely available. Please see FAQ for details.